Collaborative Arrangement, Achievement Levels of Commercial Performance, Period

No definition available.

Name:	exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix:	exel_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum amount eligible for commercial milestones under collaborations agreement.

+ References

No definition available.

+ Details

Name:	exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payment Of Reimbursements From Collaboration Arrangement

+ References

No definition available.

+ Details

Name:	exel_PaymentOfReimbursementsFromCollaborationArrangement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percent of royalty on net sale.

+ References

No definition available.

+ Details

Name:	exel_PercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent

+ References

No definition available.

+ Details

Name:	exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Tier

+ References

No definition available.

+ Details

Name:	exel_RoyaltyTier
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront and milestone payments.

+ References

No definition available.

+ Details

Name:	exel_UpfrontAndMilestonePayments
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_RoyaltytierAxis=exel_InitialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_RoyaltytierAxis=exel_SecondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_RoyaltytierAxis=exel_FinalTierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_MilestoneObjectiveAxis=exel_HCCFilingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	exel_MilestoneObjectiveAxis=exel_HCCAcceptanceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=exel_CabometyxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)	1 Months Ended		3 Months Ended		12 Months Ended
	Sep. 30, 2016 USD ($)	Oct. 31, 2008	Dec. 29, 2017 USD ($)	Dec. 29, 2017 CAD	Dec. 29, 2017 USD ($)	Dec. 30, 2016 USD ($)	Mar. 31, 2017 USD ($)	Feb. 29, 2016 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued collaboration liabilities			$ 16,643,000		$ 16,643,000	$ 541,000
Current portion of deferred revenue			31,984,000		31,984,000	19,665,000
Long-term portion of deferred revenue			238,520,000		238,520,000	237,094,000
GlaxoSmithKline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale		3.00%
Collaborative arrangement with Ipsen [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront and milestone payments					210,000,000
Revenue recognized, milestones					$ 45,000,000	$ 20,000,000
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement								$ 209,000,000
Maximum amount eligible for commercial milestones under collaborations agreement								546,000,000
Research and development arrangement performed for others, reimbursement for costs incurred, percent					35.00%
Payment of reimbursements from collaboration arrangement			3,900,000
Collaboration period to achieve specified levels of commercial performance					10 years
Current portion of deferred revenue			19,000,000		$ 19,000,000
Long-term portion of deferred revenue			$ 210,200,000		$ 210,200,000
Collaborative arrangement with Ipsen [Member] \| Initial [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale			2.00%	2.00%
Royalty tier			$ 50,000,000	CAD 30,000,000.0
Collaborative arrangement with Ipsen [Member] \| Second [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					12.00%
Royalty tier					$ 100,000,000
Collaborative arrangement with Ipsen [Member] \| Final tier [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty tier					$ 150,000,000
Collaborative arrangement with Ipsen [Member] \| Final tier [Member] \| Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					22.00%
Collaborative arrangement with Ipsen [Member] \| Final tier [Member] \| Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					26.00%
Collaborative arrangement with Ipsen [Member] \| HCC Filing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement								10,000,000
Collaborative arrangement with Ipsen [Member] \| HCC Acceptance [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement								$ 40,000,000
Collaborative arrangement with Ipsen, approval of product by EC in Second-Line RCC [Member] \| Cabometyx [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized, milestones	$ 60,000,000
Restatement adjustment [Member] \| Collaborative arrangement with Ipsen [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment reclassified							$ 9,000,000
Accrued collaboration liabilities							$ 9,000,000